Next 10 |
home / stock / ortif / ortif news
(NewsDirect) ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,0...
Ortho Regenerative Technologies ( OTCQB:ORTIF ) has changed its corporate name to ChitogenX Inc. The new name to better represent company's proprietary technology platform expanded applications beyond orthopedics The company's shares are expected to begin trading on the CS...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES CORPORATE NAME CHANGE TO CHITOGENX Canada NewsWire New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL , Sept. 7, 2022 /CNW Telbec/ ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire First patient surgery completed; additional surgeries already scheduled 8 clinical centres now fully initi...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS Canada NewsWire MONTREAL , July 22, 2022 /CNW Telbec/ - Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTCQB: ORTIF) (" Ortho " o...
Unmet large market needs. Ortho Regenerative Technologies Inc. (Ortho RTI) is advancing its RESTORE regenerative medicine platform in rotator cuff tears and meniscus tears to improve healing. Rotator cuff and meniscus tears have high failure rates due to insufficient healing and tissue degener...
Ortho Regenerative Technologies press release (OTCQB:ORTIF): Q1 GAAP EPS of -C$0.02. Cash balance as April 30, 2022 of C$2.19M For further details see: Ortho Regenerative Technologies GAAP EPS of -C$0.02
ORTHO REGENERATIVE TECHNOLOGIES REPORTS ITS FIRST QUARTER 2023 RESULTS Canada NewsWire Patients recruitment initiated for U.S. Phase I/II rotator cuff tear repair clinical trial in June 2023 Philippe Deschamps appointed as new CEO Signing of M...
ORTHO REGENERATIVE TECHNOLOGIES INITIATES PATIENTS RECRUITMENT FOR ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire Contracting procedures completed for 6 of the 10 clinical trial sites 5 sites fully activated, with ongoing patien...
ORTHO REGENERATIVE TECHNOLOGIES RECEIVES $500,000 AXELYS GRANT TO ADVANCE ORTHO-M DEVELOPMENT FOR MENISCUS REPAIR Canada NewsWire Meniscus indication confirms proprietary technology platform multi-indications potential Grant to accelerate development of sec...
News, Short Squeeze, Breakout and More Instantly...
Ortho Regenerative Technologies Inc Company Name:
ORTIF Stock Symbol:
OTCMKTS Market:
Ortho Regenerative Technologies Inc Website:
(NewsDirect) ChitogenX CEO Phil Deschamps joined Proactive's Natalie Stoberman with news of the company's latest federal grant and partnership deal with Polytechnique Montréal to expand the ORTHO- R platform in regenerative medicine. Deschamps said the company has obtained a $3,472,0...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES CORPORATE NAME CHANGE TO CHITOGENX Canada NewsWire New Name to better represent Company's proprietary technology platform expanded applications beyond orthopedics MONTREAL , Sept. 7, 2022 /CNW Telbec/ ...
ORTHO REGENERATIVE TECHNOLOGIES ANNOUNCES ENROLLMENT OF FIRST PATIENT IN ITS U.S. PHASE I/II ROTATOR CUFF TEAR REPAIR CLINICAL TRIAL Canada NewsWire First patient surgery completed; additional surgeries already scheduled 8 clinical centres now fully initi...